Diagnostics & Research Stocks
Diagnostics & Research filings and news · newest 5:21 PM ET · How scores work
Fri, Oct 97 events
9LABStandard BioTools Inc.Standard BioTools Files Final Proxy for Treeline Reverse Merger — 84% Dilution, 1-for-20 to 1-for-40 Reverse Split7QUCYQuantum Cyber N.V.Quantum Cyber Launches $100M ATM Program with Titan Partners7ISPCiSpecimen Inc.iSpecimen Lowers Reverse-Split Vote Bar to Plurality, Adjourns to Oct 308BIAFbioAffinity Technologies, Inc.bioAffinity Closes $4M Registered Direct Offering and Suspends ATM7ISPCiSpecimen Inc.iSpecimen Shareholders Approve Dilutive Financing and Foldlab Deal; Reverse Split Vote Delayed to Oct 308BIAFbioAffinity Technologies, Inc.bioAffinity Prices $4M Registered Direct Offering at $6.122 with Warrants7NTRANatera, Inc.FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Assay
Thu, Oct 82 events
7GHGuardant Health, Inc.Guardant360 CDx Wins European Approval as Companion Diagnostic for AstraZeneca's ETCAMAH7BIAFbioAffinity Technologies, Inc.bioAffinity Raises $4M in Registered Direct Offering Priced At-The-Market
Wed, Oct 74 events
7XWELXWELL, Inc.XWELL Sets October 28 Vote on $13M Sale of XpresSpa and XpresTest7XWELXWELL, Inc.XWELL Pays $2.7M to Buy Out XpresTest Restricted Stock Ahead of $13M Sale7NEOGNeogen CorporationNeogen Q1 FY2027: Revenue Up 6.5%, Operating Loss Narrows to $1.8M, Genomics Sale Still Pending7BLLNBillionToOne, Inc.Peer-Reviewed Study Shows BillionToOne's Tissue-Free Assay Matches or Beats Tumor-Informed Monitoring
Tue, Oct 67 events
7PSNLPersonalis, Inc.Personalis Clears HSR Antitrust Review for Tempus Merger7NEOGNeogen CorporationNeogen Lifts FY2027 Outlook on Q1 Beat and New Imaging Partnership8NEOGNEOGEN CORPNeogen Q1 Revenue Beats, Raises FY27 Guidance on Strong Core Growth7NEONEOGENOMICS INCNeoGenomics Plunges 12% as Leadership Shakeup and Q3 Beat Fail to Impress7BIAFbioAffinity Technologies, Inc.CyPath Lung Sales Double in Q3 as Physician Adoption Surges 89%7BIAFbioAffinity Technologies, Inc.CyPath Lung Sales Double Through Q3 2026; New VA-Focused Distribution Deal7NTRANatera, Inc.Signatera Shows 100% Sensitivity in Rectal Cancer at ASTRO 2026
Mon, Oct 54 events
7LABStandard BioTools Inc.Standard BioTools Divests Microfluidics Business to ARCHIMED7NEONEOGENOMICS INCNeoGenomics Names Warren Stone CEO, Posts Preliminary Q3 Revenue of $209M7NEONEOGENOMICS INCNeoGenomics Names Warren Stone CEO, Prelim Q3 Revenue Tops $209M7NTRANatera, Inc.Natera's Signatera to Guide CDK4/6 Therapy in Global Phase III Breast Cancer Trial
Fri, Oct 21 event
Thu, Oct 12 events
9NDRAENDRA Life Sciences Inc.ENDRA Files S-4 for Reverse Merger with Noble Africa: ASP Isotopes to Control 98.8% of Voting Power7NDRAENDRA Life Sciences Inc.ENDRA Amends Noble Africa Merger Terms, Removes Warrant Ownership Cap
Wed, Sep 302 events
8LABStandard BioTools Inc.Standard BioTools Swaps Mass Cytometry Buyer: Element Biosystems Replaces Multiplex Bio in $5.5M Deal8LABStandard BioTools Inc.Standard BioTools Swaps Mass Cytometry Buyer: Element Biosystems Replaces Multiplex Bio in $5.5M Deal
Tue, Sep 293 events
8NEOGNEOGEN CORPFDA Warning Letter: Neogen's Hycoat Linked to 20 Horse Deaths, Contamination Found7BIAFbioAffinity Technologies, Inc.bioAffinity Seeks Stockholder Approval for Warrant Exercise, New Offering Authorization, and Authorized Share Decrease7MBAIMBody AI Ltd.MBody AI's Robots Go Commercial at Mohegan Sun, Multi-Year Expansion Eyed
Mon, Sep 282 events
8MEDPMedpace Holdings, Inc.Medpace Chairman Troendle Sold ~$125M in Stock Over Six Weeks7QGENQIAGEN N.V.FDA Clears QIAGEN's Gram-Negative Panel, Completing U.S. Bloodstream Infection Portfolio
Thu, Sep 242 events
7CRLCharles River Laboratories International, Inc.Charles River Reaffirms 2026 Guidance at Upper End, Sets 2030 Targets8CRLCharles River Laboratories International, Inc.Charles River Unveils 2030 Targets: 5-7% Growth, ~24% Margin, $300M Savings Plan
Wed, Sep 233 events
9GRALGRAIL, Inc.FDA Panel Backs GRAIL's Galleri Cancer Test, Clearing Key Hurdle8GRALGRAIL, Inc.Grail Trading Halted Ahead of FDA AdCom on Galleri Blood Test8ILMNIllumina, Inc.Grail Trading Halted Ahead of FDA Panel Review of Galleri Cancer Test
Tue, Sep 221 event
Diagnostics & Research companies on Wiseek (55)
Each company page tracks that company's SEC filings, news and market data.
How Wiseek picks and scores these
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a diagnostics & research company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
See the full Healthcare sector feed.